US Edition
GLP-1 Drugs Appear To Lower Cancer Risk
- Researchers in Israel studied over 6,300 obese adults with type 2 diabetes from 2010 to 2018 to evaluate cancer risk related to first-generation GLP-1 drugs or weight-loss surgery.
- The study followed participants until December 2023 to determine cancer development, noting that obesity and diabetes increase risk for cancers like breast, colon, and uterus cancer.
- Nearly 300 participants developed obesity-related cancers during an average 7.5-year follow-up, with breast cancer accounting for 26% of cases, and GLP-1 drugs showed a 41% lower cancer risk than surgery.
- Lead researchers said GLP-1 drugs reduce cancer risk beyond weight loss through multiple mechanisms including inflammation reduction, while newer, more potent GLP-1 medications may offer greater advantages though were not studied here.
- These findings suggest GLP-1 drugs could provide less invasive cancer risk reduction than surgery, but further research is needed to understand mechanisms and effects on non-obesity-related cancers.
32 Articles
32 Articles
Popular weight-loss meds also curb alcoholism, tests show · American Wire News
A popular pharmaceutical intervention for weight loss may also have the potential to curb alcoholism, as researchers observed a “commonality of function.” Between those who swear by the medications and the horror stories of side effects, the jury remains out on the risk/reward balance when it comes to glucagon-like peptide-1 drugs, better known as GLP-1s. That said, researchers from Ireland and Saudi Arabia teamed together to reveal that the sam…
Tioga Publishing
GLP-1 Drugs Appear To Lower Cancer Risk
Key Takeaways
Weight-loss medications may also benefit common medical problem, study finds
Weight-loss medications known as glucagon-like peptide-1 (GLP-1) agonists, which have gained popularity for treating type 2 diabetes and obesity, have been shown to have the surprising secondary benefit of reducing alcohol intake.A team of international researchers from Ireland and Saudi Arabia followed 262 adult patients with obesity who started taking two GLP-1 medications: liraglutide or semaglutide.Among the regular drinkers, weekly alcohol …
Coverage Details
Bias Distribution
- 50% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
